NEW YORK – Amgen said on Thursday it will acquire Five Prime Therapeutics in a tender offer valued at $1.9 billion, a move that will bring Five Prime's anti-FGFR2b antibody drug bemarituzumab to Amgen's oncology portfolio.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.